J. Kim
10 Papers
J. Kim is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 10 publications.
Chat about Author
Papers
56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
D. Oh,A. Ruth He,S. Qin,L. T. Chen,Takuji Okusaka,Andrea R. Vogel,J. Kim,Thatthan Suksombooncharoen,Mark Lee,Michiko Kitano,Howard A. Burris,Mohamed Bouattour,Suebpong Tanasanvimon,Renata Zaucha,Antonio Avallone,J. Cundom,Nana Rokutanda,Magdalena Watras,G. Cohen,Juan W. Valle +19 more
TL;DR: In this article , the authors report an updated OS and safety analysis for TOPAZ-1 (NCT03875235) and show that D + GC significantly improved OS versus PBO + GC in pts with advanced BTC (hazard ratio [HR, 0.80; 95% confidence interval [CI], 0.66-0.97; p=0.021).
34
529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer
Shantimoy Banerjee,Martina Imbimbo,Patricia Roxburgh,J. Kim,M. Kim,Ruth Plummer,S.M. Stemmer,B. You,M. Ferguson,R. Penson,David M. O'Malley,K. Meyer,H. F. Gao,Helen K. Angell,A. Tablante Nunes,S. Domchek,Yvette Drew +16 more
TL;DR: The MEDIOLA (NCT02734004) study evaluated the efficacy and safety of olaparib+durvalumab (O+D doublet cohort) and O+D+bevacizumab(O +D+B triplet cohort), in patients with non-germline BRCA-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) as mentioned in this paper .
21
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
Kyle Francis,S. I. Kim,Michael Friedlander,Val Gebski,Isabelle Ray-Coquard,A. Clamp,R. Penson,Aabha Oza,Tamar Perri,Tomasz Huzarski,Cristina Martin-Lorente,Sabrina Chiara Cecere,N. Colombo,Beyhan Ataseven,Keiichi Fujiwara,GS Sonke,Ignace Vergote,Eric Pujade-Lauraine,J. Kim,C.K. Lee +19 more
TL;DR: In this paper , the authors used data from the SOLO2 trial to evaluate the impact of dose alterations on survival outcomes and identified baseline characteristics associated with dose alteration, including adverse event (AE)-associated olaparib interruption, dose reduction, and discontinuation in 50, 28, and 17% of patients.
19
Stage matched head-to-head comparison between urachal carcinoma and urothelial bladder cancer: TNM-stage based analysis from a national multicenter database
S. Song,Jjh Kim,Joo-Hyun Nam,Yun Hee Ko,J. Kim,S. Jung,S. Kang,J. Park,H. K. Seo,H. Kim,Byong Chang Jeong,T Kim,S.Y. Choi,Jong Kil Nam,Ja Yoon Ku,Kwan Joong Joo,Woo Soon Jang,Y. Yoon,Su Jin Yun,S K Hong,Jong Jin Oh +20 more